Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study

John Timmerman; David Lavie; Nathalie A. Johnson; Abraham Avigdor; Peter Borchmann; Charalambos Andreadis; Ali Bazargan; Gareth P. Gregory; Colm Keane; Inna Tzoran; Vladan Vucinic; Pier Luigi Zinzani; Hong Zhang; Palavi Pillai; Patricia Marinello; Alex F. Herrera

doi:10.1200/JCO.2022.40.16_suppl.7545

Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study

John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Tzoran, Vladan Vucinic, Pier Luigi Zinzani, Hong Zhang, Palavi Pillai, Patricia Marinello, Alex F. Herrera

Medicine Monash Health

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	7545
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	40
Issue number	16 Supplement
DOIs	https://doi.org/10.1200/JCO.2022.40.16_suppl.7545
Publication status	Published - Jun 2022
Event	American Society of Clinical Oncology Annual Meeting (ASCO 2022) - Chicago, United States of America Duration: 3 Jun 2022 → 7 Jun 2022 https://ascopubs.org/toc/jco/40/16_suppl (ASCO 2022 Annual Meeting I) https://ascopubs.org/toc/jco/40/17_suppl (ASCO 2022 Meeting II) https://meetings.asco.org/meetings/2022-asco-annual-meeting/288/program-guide/scheduled-sessions

Access to Document

10.1200/JCO.2022.40.16_suppl.7545

Cite this

Timmerman, J., Lavie, D., Johnson, N. A., Avigdor, A., Borchmann, P., Andreadis, C., Bazargan, A., Gregory, G. P., Keane, C., Tzoran, I., Vucinic, V., Zinzani, P. L., Zhang, H., Pillai, P., Marinello, P., & Herrera, A. F. (2022). Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study. Journal of Clinical Oncology, 40(16 Supplement), Article 7545. https://doi.org/10.1200/JCO.2022.40.16_suppl.7545

@article{524f8bc57c0f4498a8003714ac3c9738,

title = "Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study",

author = "John Timmerman and David Lavie and Johnson, \{Nathalie A.\} and Abraham Avigdor and Peter Borchmann and Charalambos Andreadis and Ali Bazargan and Gregory, \{Gareth P.\} and Colm Keane and Inna Tzoran and Vladan Vucinic and Zinzani, \{Pier Luigi\} and Hong Zhang and Palavi Pillai and Patricia Marinello and Herrera, \{Alex F.\}",

year = "2022",

month = jun,

doi = "10.1200/JCO.2022.40.16\_suppl.7545",

language = "English",

volume = "40",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology ",

number = "16 Supplement",

note = "American Society of Clinical Oncology Annual Meeting (ASCO 2022), ASCO 2022 ; Conference date: 03-06-2022 Through 07-06-2022",

url = "https://ascopubs.org/toc/jco/40/16\_suppl, https://ascopubs.org/toc/jco/40/17\_suppl, https://meetings.asco.org/meetings/2022-asco-annual-meeting/288/program-guide/scheduled-sessions",

}

Timmerman, J, Lavie, D, Johnson, NA, Avigdor, A, Borchmann, P, Andreadis, C, Bazargan, A, Gregory, GP, Keane, C, Tzoran, I, Vucinic, V, Zinzani, PL, Zhang, H, Pillai, P, Marinello, P & Herrera, AF 2022, 'Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study', Journal of Clinical Oncology, vol. 40, no. 16 Supplement, 7545. https://doi.org/10.1200/JCO.2022.40.16_suppl.7545

Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study. / Timmerman, John; Lavie, David; Johnson, Nathalie A. et al.
In: Journal of Clinical Oncology, Vol. 40, No. 16 Supplement, 7545, 06.2022.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment

T2 - American Society of Clinical Oncology Annual Meeting (ASCO 2022)

AU - Timmerman, John

AU - Lavie, David

AU - Johnson, Nathalie A.

AU - Avigdor, Abraham

AU - Borchmann, Peter

AU - Andreadis, Charalambos

AU - Bazargan, Ali

AU - Gregory, Gareth P.

AU - Keane, Colm

AU - Tzoran, Inna

AU - Vucinic, Vladan

AU - Zinzani, Pier Luigi

AU - Zhang, Hong

AU - Pillai, Palavi

AU - Marinello, Patricia

AU - Herrera, Alex F.

PY - 2022/6

Y1 - 2022/6

U2 - 10.1200/JCO.2022.40.16_suppl.7545

DO - 10.1200/JCO.2022.40.16_suppl.7545

M3 - Meeting Abstract

SN - 0732-183X

VL - 40

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16 Supplement

M1 - 7545

Y2 - 3 June 2022 through 7 June 2022

ER -